FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Multiple Insightra Medical Violations Cited

[ Price : $8.95]

FDA warns Clarksville, TN-based Insightra Medical about multiple violations in its production of intra-aortic balloon pump cathete...

FDA Study Finds Liver Risks Associated with CBD

[ Price : $8.95]

A new FDA clinical trial finds that cannabidiol may cause liver enzyme elevations in otherwise healthy adults raising new concern...

Expanded Parkinsons Use OKd for Insightec Device

[ Price : $8.95]

FDA approves an expanded indication for Insightecs Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatme...

Biotech Leaders Support Access to Mifepristone

[ Price : $8.95]

A letter from dozens of biotechnology industry executives and investors urges FDA commissioner Marty Makary to reject efforts to r...

FDA Drops REMS Need for ERA Meds

[ Price : $8.95]

FDA drops REMS requirements covering embryofetal toxicity risk in endothelin receptor antagonists.

CGMP Violations at Exela Pharma Sciences

[ Price : $8.95]

FDA warns Lenoir, NC-based Exela Pharma Sciences about CGMP violations in its work as a drug manufacturing outsourcing facility.

Support for Biosimilar Legislation

[ Price : $8.95]

Forty health advocacy groups led by the Association for Accessible Medicines voice their support for legislation to eliminate the ...

FDA Prodded to Improve Surrogate Endpoint Transparency

[ Price : $8.95]

A Federation of American Scientists online paper says FDA, other federal research agencies, and Congress should take steps to incr...

Taiho Reports Unfavorable DMD Drug Data

[ Price : $8.95]

Taiho Pharmaceutical reports disappointing data from its Phase 3 extension study of TAS-205 (pizuglanstat) in patients with Duchen...

FDA Urged to Expand Real-World Data Use

[ Price : $8.95]

A bioethicists opinion piece in The Hill says FDA needs to expand its reliance on real-world clinical data to monitor the safety a...